Texas cancer probe draws NCI scrutiny

December 14, 2012 by Paul J. Weber

(AP)—The federal National Cancer Institute says it's taking a fresh look at a troubled $3 billion cancer-fighting effort already being scrutinized by prosecutors and lawmakers in Texas.

The U.S. government's agency confirmed Friday that upheaval within the Cancer Prevention and Research Institute of Texas caught its attention. NCI spokeswoman Aleea Farrakh Khan told The Associated Press that officials are "evaluating recent events" at CPRIT.

CPRIT is on an exclusive list of NCI-approved funding entities, which includes the . The designation is a federal seal-of-approval that signals high peer review standards and conflict of interest policies.

Khan says NCI has made no decisions about CPRIT or contacted the agency directly.

Prosecutors are investigating CPRIT following an $11 million award to a private company that bypassed review.

Explore further: Researchers train promotoras to combine mobile technology, cancer prevention messages

shares

Related Stories

Prevalence of screening for Lynch syndrome varies

February 24, 2012

(HealthDay) -- Screening for Lynch syndrome, the most common form of inherited colorectal cancer, after a colorectal cancer diagnosis is common at comprehensive cancer centers but not community hospitals, according to a study ...

Cancer agency OK'd faulty $11M grant

November 29, 2012

(AP)—Texas' embattled $3 billion cancer-fighting agency approved an $11 million grant to a biomedical company even though the proposal wasn't reviewed.

Recommended for you

Cell phones and rats: Study explores radiation exposure

May 28, 2016

For some years research teams have explored and attempted to sort out any evidence concerning a cause-effect situation with mobile phones and cancer. Interest in the question does not disappear. Scientific groups prefer to ...

Scientists block breast cancer cells from hiding in bones

May 25, 2016

Scientists at the Duke Cancer Institute have identified a molecular key that breast cancer cells use to invade bone marrow in mice, where they may be protected from chemotherapy or hormonal therapies that could otherwise ...

Genetic sequencing reveals drug resistance growth

May 25, 2016

The rate at which genetically mutated cancer cells grow may help explain why patients with a common form of leukemia develop treatment resistance, according to new research led by a Weill Cornell Medicine investigator. The ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.